FDA accepts Allergan’s Vraylar for review
The US Food and Drug Administration has accepted for review an application from Allergan to expand the scope of its antipsychotic Vraylar.
Read More
Tag: bipolar I depression
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
